Endo Will Purchase Par Pharma For $8B Amid Hunt for More Deals

Endo International Plc, the maker of pain drugs like Opana and Percocet, agreed to buy Par Pharmaceutical Holdings Inc. for $8.05 billion in cash and stock as part of a plan to ignite sales growth and pursue more acquisitions.

In exchange for Par, the drugmaker agreed to give private-equity firm TPG Capital $1.55 billion in stock and $6.5 billion in cash, and will assume Par’s debt, the companies said in a statement May 18. The takeover will create a generic-drug business that is among the top 5 in U.S. sales, the companies said, and will boost Endo’s earnings in the ...